Why Taysha Gene Therapies (TSHA) is on investors’ radar

Taysha Gene Therapies (TSHA) has drawn fresh attention after recent trading, with the stock closing at $6.43 and showing strong gains over the past month and past 3 months. Investors are now weighing these moves against its underlying gene therapy pipeline.

Beyond the recent surge, Taysha Gene Therapies has seen strong momentum build over the past year, with a 1-year total shareholder return that is more than 4x and a very large 3-year total shareholder return, despite a weaker 5-year record. Recent buying interest appears tied more to changing expectations around its gene therapy programs than to any single event, as investors reassess both growth potential and risk in early stage biotech.

If this kind of sharp move has you looking at other high growth names in healthcare, it can be helpful to compare Taysha with a wider group of AI driven healthcare opportunities via 35 healthcare AI stocks

With TSHA up sharply over 1 year and trading at a large discount to analyst targets and some intrinsic value estimates, you need to ask whether there is still mispricing here or whether the market is already accounting for future growth.

Most Popular Narrative: 44.4% Undervalued

The most followed valuation narrative currently points to a fair value of $11.57 for Taysha Gene Therapies versus the last close at $6.43, framing a wide gap that rests heavily on its Rett syndrome program.

Progress in the clinical development of TSHA-102, particularly moving towards the pivotal phase of the REVEAL trials with promising safety and efficacy data, could enhance investor confidence and potentially lead to future revenue growth once regulatory approval is achieved. Ongoing constructive discussions with the FDA about the regulatory pathway for TSHA-102, including potential expedited approval mechanisms like the RMAT designation, may accelerate product approval and market entry, thereby impacting future earnings positively.

Curious how a loss making biotech can still be tied to a high fair value. The narrative leans on rapid revenue expansion, higher margins and a rich future earnings multiple. Want to see which assumptions really do the heavy lifting.

Based on that narrative, Taysha Gene Therapies is described as trading at a very large discount to its fair value estimate of $11.57, using a 7.16% discount rate to bring projected revenue growth, margin shifts and share count changes back to today. The result hinges on expectations that future earnings and cash flows from the Rett syndrome program and broader pipeline can justify a much higher valuation than the current share price.

Result: Fair Value of $11.57 (UNDERVALUED)

However, this hinges on successful Rett data and smooth FDA interactions. Any clinical setbacks or regulatory delays could quickly challenge the undervalued story.

Next Steps

With mixed sentiment around Taysha Gene Therapies, it helps to move quickly, review the complete picture yourself, and then decide where you stand based on the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

If Taysha has caught your eye, do not stop here. Widen your watchlist with a few focused stock ideas that could help inform your next move.

• Target potential value upside by scanning a curated pool of companies trading below their estimated worth using the 59 high quality undervalued stocks.
• Strengthen the income side of your portfolio with companies offering substantial yields by checking out the 11 dividend fortresses.
• Prioritise resilience and capital protection by reviewing companies that clear strict balance sheet checks through the solid balance sheet and fundamentals stocks screener (42 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.